EGFR and non-small cell lung carcinoma: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, such as erlotinib, have been proven to benefit NSCLC by inhibiting the activation of EGFR gene mutations (Paez et al., 2004).